Novartis agreed a $9.7 billion deal to acquire the US-based The Medicines Company, it announced Sunday. The transaction was unanimously approved by the boards of both companies and Novartis will pay $85 per share. This takeover comes following The...

Een discussie die in mijn beleving nooit is weggeweest lijkt weer op te laaien. Werkt reclame eigenlijk wel? Worden de investeringen in reclame en media wel terugverdiend? Artikelen uit De Correspondent worden regelmatig in verschillende gremia...

MSD’s top-selling immunotherapy Keytruda (pembrolizumab) has secured another approval from the European Commission, this time in the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in...